Literature DB >> 27270514

National Early Rectal Cancer Treatment Revisited.

Tore Stornes1, Arne Wibe, Arild Nesbakken, Tor Å Myklebust, Birger H Endreseth.   

Abstract

BACKGROUND: Treatment of early stage rectal cancer has excellent oncological results. To reduce treatment-related mortality and morbidity and improve functional results, a focus on local resections is increasingly important.
OBJECTIVE: The purpose of this study was to compare outcomes after transanal endoscopic microsurgery and total mesorectal excision for early stage rectal cancer (T1 + T2) in Norway.
DESIGN: This was an observational study based on prospective data from the Norwegian Colorectal Cancer Registry. SETTINGS: The study was conducted as a national, population-based study. PATIENTS: All 543 patients with T1 and 1593 patients with T2 rectal cancer without distant metastases that was treated by transanal endoscopic microsurgery or total mesorectal excision without radiochemotherapy during 2000-2009 were included. MAIN OUTCOME MEASURES: The primary outcomes were 5-year relative survival and 5-year local recurrence rate.
RESULTS: Among 543 patients with T1 cancer, the 5-year overall survival rate was 65.3% after transanal endoscopic microsurgery versus 81.5% after total mesorectal excision (p = 0.012). Adjusted for age and sex there was no excess mortality for transanal endoscopic microsurgery (HR = 1.28 (95% CI, 0.8-1.9); p = 0.22). The 5-year relative survival rate was 96.8% after transanal endoscopic microsurgery versus 98.2% after total mesorectal excision (p = 0.603), and the 5-year local recurrence rate was 14.5% versus 1.4% (p < 0.001). Among 1593 patients with T2 cancer, 5-year overall survival was 42.1% versus 76.1% (p < 0.001), 5-year relative survival was 65.4% versus 93.9% (p < 0.001), and 5 year local recurrence rate was 11.4% versus 4.4% in the 2 groups. LIMITATIONS: The study is limited by its observational design and that the 2 groups were different according to patient and tumor characteristics. Another limitation was the low number of transanal endoscopic microsurgery procedures.
CONCLUSIONS: Transanal endoscopic microsurgery had comparable 5-year relative survival to total mesorectal excision in T1 rectal cancer but inferior 5-year relative survival in T2 rectal cancer. Transanal endoscopic microsurgery was associated with higher local recurrence rates for both T1 and T2 tumors.

Entities:  

Mesh:

Year:  2016        PMID: 27270514     DOI: 10.1097/DCR.0000000000000591

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  19 in total

1.  Rectal cancer confined to the bowel wall: the role of 3 Tesla phased-array MR imaging in T categorization.

Authors:  Hale Çolakoğlu Er; Elif Peker; Ayşe Erden; İlhan Erden; Ethem Geçim; Berna Savaş
Journal:  Br J Radiol       Date:  2017-11-21       Impact factor: 3.039

2.  Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection.

Authors:  Oliver K Jawitz; Mohamed A Adam; Megan C Turner; Brian F Gilmore; John Migaly
Journal:  Surgery       Date:  2019-03-21       Impact factor: 3.982

3.  Risk of recurrence after local resection of T1 rectal cancer: a meta-analysis with meta-regression.

Authors:  Nik Dekkers; Hao Dang; Jolein van der Kraan; Saskia le Cessie; Philip P Oldenburg; Jan W Schoones; Alexandra M J Langers; Monique E van Leerdam; Jeanin E van Hooft; Yara Backes; Katarina Levic; Alexander Meining; Giorgio M Saracco; Fabian A Holman; Koen C M J Peeters; Leon M G Moons; Pascal G Doornebosch; James C H Hardwick; Jurjen J Boonstra
Journal:  Surg Endosc       Date:  2022-06-30       Impact factor: 4.584

4.  Transanal minimal invasive surgery (TAMIS): safety and feasibility for the resection of benign and malignant lesions of the rectum.

Authors:  Asif Mehraj; Najmus Saqib; Rauf Wani; Nisar Chowdri; Fazl Parray; Mudassir Khan
Journal:  Turk J Surg       Date:  2021-03-22

5.  Prognosis of Patients Over 60 Years Old With Early Rectal Cancer Undergoing Transanal Endoscopic Microsurgery - A Single-Center Experience.

Authors:  Mingqing Zhang; Yongdan Zhang; Haoren Jing; Lizhong Zhao; Mingyue Xu; Hui Xu; Siwei Zhu; Xipeng Zhang
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

6.  Outcomes of Local Excision plus Chemoradiotherapy in Patients with T1 Rectal Cancer.

Authors:  Toshiyuki Suzuki; Sotaro Sadahiro; Akira Tanaka; Kazutake Okada; Gota Saito; Hiroshi Miyakita; Takeshi Akiba; Hiroshi Yamamuro
Journal:  Oncology       Date:  2018-06-15       Impact factor: 2.935

7.  SEOM Clinical Guideline of localized rectal cancer (2016).

Authors:  E González-Flores; F Losa; C Pericay; E Polo; S Roselló; M J Safont; R Vera; J Aparicio; M T Cano; C Fernández-Martos
Journal:  Clin Transl Oncol       Date:  2016-11-30       Impact factor: 3.405

8.  Survival analysis of local excision vs total mesorectal excision for middle and low rectal cancer in pT1/pT2 stage and intermediate pathological risk.

Authors:  I-Li Lai; Jeng-Fu You; Yih-Jong Chern; Wen-Sy Tsai; Jy-Ming Chiang; Pao-Shiu Hsieh; Hsin-Yuan Hung; Chien-Yuh Yeh; Sum-Fu Chiang; Cheng-Chou Lai; Rei-Ping Tang; Jinn-Shiun Chen; Yu-Jen Hsu
Journal:  World J Surg Oncol       Date:  2019-12-09       Impact factor: 2.754

9.  Prevalence of nodal involvement in rectal cancer after chemoradiotherapy.

Authors:  H E Haak; G L Beets; K Peeters; P J Nelemans; V Valentini; C Rödel; L Kuo; F A Calvo; J Garcia-Aguilar; R Glynne-Jones; S Pucciarelli; J Suarez; G Theodoropoulos; S Biondo; D M J Lambregts; R G H Beets-Tan; M Maas
Journal:  Br J Surg       Date:  2021-10-23       Impact factor: 11.122

Review 10.  Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment.

Authors:  S E van Oostendorp; L J H Smits; Y Vroom; R Detering; M W Heymans; L M G Moons; P J Tanis; E J R de Graaf; C Cunningham; Q Denost; M Kusters; J B Tuynman
Journal:  Br J Surg       Date:  2020-09-16       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.